LIMAS

Test organism Log10 reduction % reduction

TRAPS AND KILLS IMMEDIATELYViroblock technology captures cholesterol from the viral envelope to inactivate the virus and block infection.

Viroblock’s unique cyclodextrin and non-phospholipids coating acts immediately to inactivate viruses on contact.

RESPIRATORY VIRUSES CAUSE SIGNIFICANT MORBIDITY AND

COST IN AT RISK PATIENTS

In a nursing home setting, viral infection attack rates of over 60% have been reported. Among those with influenza, 52% developed pneumonia, 29% were hospitalized and 10% died of influenza-related complications (Arden et al 1986; Anon 1992; Coles et al 1992; Patriarca et al 1985)

Influenza illness in vulnerable populations, in particular immunocompromised patients, can result in devastating consequences, with severe, prolonged, and often fatal diseases(Buxton Bridges et al 2003)

Influenza infection is associated with significant morbidity in solid organ transplant patients (Vilchez 2002)

Parainfluenza virus can lead to acute allograft rejection (Vilchez 2003)

H1N1 infection increases the median hospital stay compared with seasonal influenza in paediatric cancer patients and leads to a higher mortality rate (Shah 2012)

EMERGING SEASONAL OR PANDEMIC VIRUSES HAVE A SIGNIFICANT IMPACT ON HEALTHCARE WORKERS

The Health Care Workers attack rate in nosocomical viral infection outbreaks is estimated to be as high as 60% (Bridges 2003)

Half the SARS cases in Canada (2003) were HCW (Health Canada 2003)

Large number of SARS cases were linked to aerosol generating clinical procedures e.g. intubation and bronchoscopy (Peries 2003)

Dentists have a significantly elevated presence of antibodies to influenza A and B than the general population (Davies 1994)

15.5% of reported exposures to infection control officers for paramedics are for respiratory viral infection (Sayed 2011)

VIRUSES ARE A PROBLEM ! AEROSOLS ARE AN IMPORTANT MODE OF INFLUENZA TRANSMISSION“Aerosol transmission accounts for approximately half of all transmission events. This implies that measures to reduce transmission by contact or large droplets may not be sufficient to control influenza transmission.” (Cowling, 2013)

The VBHF002 mask consistently delivers between 1.5 and 2.0 log’s more protection than masks without Viroblock technology in these tests**.

PERFORMANCE

* there WERE NO DETECTED BACTERIA** Viroblock masks are tested in-vitro using live virus in a standardized aerosol filtration test method : ATSM F2101

BROAD SPECTRUM OF ACTIONAerobiology testing confirms that the VBHF002 mask traps and kills both enveloped viruses and bacteria

PRODUCT

LIMAS

LIMAS